- Home
- HAFN vs IOVA Comparison
HAFN vs IOVA Comparison
Compare HAFN & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- IOVA
- Stock Information
- Founded
- HAFN 2012
- IOVA 2007
- Country
- HAFN Bermuda
- IOVA United States
- Employees
- HAFN N/A
- IOVA N/A
- Industry
- HAFN
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HAFN
- IOVA Health Care
- Exchange
- HAFN Nasdaq
- IOVA Nasdaq
- Market Cap
- HAFN 4.0B
- IOVA 3.6B
- IPO Year
- HAFN N/A
- IOVA N/A
- Fundamental
- Price
- HAFN $6.98
- IOVA $9.86
- Analyst Decision
- HAFN Strong Buy
- IOVA Strong Buy
- Analyst Count
- HAFN 1
- IOVA 10
- Target Price
- HAFN $10.00
- IOVA $24.80
- AVG Volume (30 Days)
- HAFN 1.1M
- IOVA 6.0M
- Earning Date
- HAFN 01-01-0001
- IOVA 11-05-2024
- Dividend Yield
- HAFN 23.05%
- IOVA N/A
- EPS Growth
- HAFN N/A
- IOVA N/A
- EPS
- HAFN 1.56
- IOVA N/A
- Revenue
- HAFN $2,970,261,000.00
- IOVA $32,772,000.00
- Revenue This Year
- HAFN N/A
- IOVA $13,836.92
- Revenue Next Year
- HAFN N/A
- IOVA $183.20
- P/E Ratio
- HAFN $4.40
- IOVA N/A
- Revenue Growth
- HAFN 18.39
- IOVA 13669.75
- 52 Week Low
- HAFN $6.85
- IOVA $3.21
- 52 Week High
- HAFN $8.99
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- IOVA 44.62
- Support Level
- HAFN N/A
- IOVA $10.32
- Resistance Level
- HAFN N/A
- IOVA $11.80
- Average True Range (ATR)
- HAFN 0.00
- IOVA 0.60
- MACD
- HAFN 0.00
- IOVA -0.25
- Stochastic Oscillator
- HAFN 0.00
- IOVA 13.44
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is a shipping company. It provides transportation of oil and oil products and also owns and operates oil product tankers. It offers fleet and bunkers services. The group operates through four segments namely LR2 Product Tankers, LR1 Product Tankers, MR and Chemical-MR segment, and Handy and Chemical-Handy segment. It generates maximum revenue from the LR1 Product Tankers segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.